Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Ketoprofen/amitriptyline/oxymetazoline; Ketoprofen/oxymetazoline/amitriptyline; OMS 103; OMS-103-HP; Oxymetazoline/amitriptyline/ketoprofen

Latest Information Update: 08 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Omeros Corporation
  • Class Dibenzocycloheptenes; Imidazoles; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Alpha 2 adrenergic receptor agonists; Lipoxygenase-cyclooxygenase inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 08 Nov 2018 Chemical structure information added
  • 16 Mar 2017 Omeros Corporation has patent protection for amitriptyline/oxymetazoline/ketoprofen for for the treatment of pain and inflammation in patients undergoing arthroscopic surgery in USA and ex-US countries
  • 03 Aug 2015 Amitriptyline/oxymetazoline/ketoprofen is still in phase III development for Postoperative pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top